6 news items
Celularity Says That Its Expected Net Sales For Q1 2024 Are Trending Ahead Of The Expectations It Announced In February For Its Advanced Biomaterial Products And Biobanking Businesses; Implements Planned 2024 SG&A Reductions And Manufacturing Ramp For Advanced Biomaterial Products
CELU
15 Apr 24
investigational products. The commercial-stage products are off-the-shelf placental-derived allografts and connective tissue matrices that are marketed
Celularity Announces Net Sales Trending Ahead of Expectations for First Quarter 2024; Implements Planned 2024 SG&A Reductions and Manufacturing Ramp for Advanced Biomaterial Products
CELU
15 Apr 24
biomaterial product pipeline consists of four commercial-stage products and three investigational products. The commercial-stage products are off
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
CELU
8 Apr 24
its investigational natural killer (NK) cell therapy programs at this year's
Celularity to Present Data Showing Senescent Cell Elimination by Off-the-Shelf Natural Killer Cells Derived from Human Placental Cells
CELU
8 Apr 24
today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year's
Kuehn Law Encourages Investors of Celularity Inc. to Contact Law Firm
CELU
22 Mar 24
(GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Celularity, Inc
l63du20vkn8jegjks74oe zsia5fz06
CELU
20 Mar 24
, Celularity received FDA Investigational New Drug Application clearance for PDA-002 in FSHD and plans to commence a phase 1/2 study in the second half
- Prev
- 1
- Next